Cargando…
Portal Vein Tumor Thrombus: No Longer a Death Sentence
Hepatocellular carcinoma (HCC) is the most common malignancy of the liver and a leading cause of cancer mortality worldwide. HCC commonly results from longstanding liver cirrhosis, which presents a host of complications and a severely diminished quality of life. Despite advancements in diagnosis, mo...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896835/ https://www.ncbi.nlm.nih.gov/pubmed/33628697 http://dx.doi.org/10.7759/cureus.12845 |
_version_ | 1783653622001696768 |
---|---|
author | Esposito, Phillip Matteo, Mika Concepcion, Carissa Montanarella, Matthew Matteo, Jerry |
author_facet | Esposito, Phillip Matteo, Mika Concepcion, Carissa Montanarella, Matthew Matteo, Jerry |
author_sort | Esposito, Phillip |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) is the most common malignancy of the liver and a leading cause of cancer mortality worldwide. HCC commonly results from longstanding liver cirrhosis, which presents a host of complications and a severely diminished quality of life. Despite advancements in diagnosis, molecular pathogenesis, and management of the complications associated with irreversible liver diseases, HCC remains an aggressive malignancy with high mortality. HCC is often invasive to adjacent vasculature, including the inferior vena cava (IVC) and portal veins, which present with rapid morbidity and patient decline. This article describes a patient with cirrhosis and HCC previously treated with cryoablation now presenting with multiple new foci and invasion of the left medial portal vein. These lesions were synchronously cryoablated. Cryoablation is typically reserved for solid tumor masses within the soft tissue or specific organs. This report illustrates a technique of directly cryoablating tumors within vessels. We achieved adequate cryoablation of the intravascular HCC portal vein tumor thrombus in the left medial portal vein. A one-month follow-up CT scan demonstrated significant portal vein macrovascular invasion (MVI) regression from 22.8 mm to 7.7 mm. Portal vein invasion by HCC presents unique challenges and traditionally precludes percutaneous or surgical therapy. Our technique shows successful cryoablation of MVI as a viable adjunct to treatment in select patients. |
format | Online Article Text |
id | pubmed-7896835 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-78968352021-02-23 Portal Vein Tumor Thrombus: No Longer a Death Sentence Esposito, Phillip Matteo, Mika Concepcion, Carissa Montanarella, Matthew Matteo, Jerry Cureus Radiology Hepatocellular carcinoma (HCC) is the most common malignancy of the liver and a leading cause of cancer mortality worldwide. HCC commonly results from longstanding liver cirrhosis, which presents a host of complications and a severely diminished quality of life. Despite advancements in diagnosis, molecular pathogenesis, and management of the complications associated with irreversible liver diseases, HCC remains an aggressive malignancy with high mortality. HCC is often invasive to adjacent vasculature, including the inferior vena cava (IVC) and portal veins, which present with rapid morbidity and patient decline. This article describes a patient with cirrhosis and HCC previously treated with cryoablation now presenting with multiple new foci and invasion of the left medial portal vein. These lesions were synchronously cryoablated. Cryoablation is typically reserved for solid tumor masses within the soft tissue or specific organs. This report illustrates a technique of directly cryoablating tumors within vessels. We achieved adequate cryoablation of the intravascular HCC portal vein tumor thrombus in the left medial portal vein. A one-month follow-up CT scan demonstrated significant portal vein macrovascular invasion (MVI) regression from 22.8 mm to 7.7 mm. Portal vein invasion by HCC presents unique challenges and traditionally precludes percutaneous or surgical therapy. Our technique shows successful cryoablation of MVI as a viable adjunct to treatment in select patients. Cureus 2021-01-21 /pmc/articles/PMC7896835/ /pubmed/33628697 http://dx.doi.org/10.7759/cureus.12845 Text en Copyright © 2021, Esposito et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Radiology Esposito, Phillip Matteo, Mika Concepcion, Carissa Montanarella, Matthew Matteo, Jerry Portal Vein Tumor Thrombus: No Longer a Death Sentence |
title | Portal Vein Tumor Thrombus: No Longer a Death Sentence |
title_full | Portal Vein Tumor Thrombus: No Longer a Death Sentence |
title_fullStr | Portal Vein Tumor Thrombus: No Longer a Death Sentence |
title_full_unstemmed | Portal Vein Tumor Thrombus: No Longer a Death Sentence |
title_short | Portal Vein Tumor Thrombus: No Longer a Death Sentence |
title_sort | portal vein tumor thrombus: no longer a death sentence |
topic | Radiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896835/ https://www.ncbi.nlm.nih.gov/pubmed/33628697 http://dx.doi.org/10.7759/cureus.12845 |
work_keys_str_mv | AT espositophillip portalveintumorthrombusnolongeradeathsentence AT matteomika portalveintumorthrombusnolongeradeathsentence AT concepcioncarissa portalveintumorthrombusnolongeradeathsentence AT montanarellamatthew portalveintumorthrombusnolongeradeathsentence AT matteojerry portalveintumorthrombusnolongeradeathsentence |